Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment.

Dale GE, Halabi A, Petersen-Sylla M, Wach A, Zwingelstein C.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00490-18. doi: 10.1128/AAC.00490-18. Print 2018 Sep.

2.

Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.

Guérard N, Oder D, Nordbeck P, Zwingelstein C, Morand O, Welford RWD, Dingemanse J, Wanner C.

Clin Pharmacol Ther. 2018 Apr;103(4):703-711. doi: 10.1002/cpt.790. Epub 2017 Aug 28.

PMID:
28699267
3.

Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment.

Guérard N, Zwingelstein C, Dingemanse J.

J Clin Pharmacol. 2017 Nov;57(11):1425-1431. doi: 10.1002/jcph.944. Epub 2017 Jun 15.

PMID:
28618006
4.

Effect of Hepatic or Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Ponesimod, a Selective S1P1 Receptor Modulator.

Guérard N, Zwingelstein C, Hoch M, Dingemanse J.

Basic Clin Pharmacol Toxicol. 2016 May;118(5):356-68. doi: 10.1111/bcpt.12516. Epub 2015 Dec 10.

5.

Discovery of camphor-derived pyrazolones as 11β-hydroxysteroid dehydrogenase type 1 inhibitors.

Gillespie P, Pietranico-Cole S, Myers M, Bilotta JA, Conde-Knape K, Fotouhi N, Goodnow RA Jr, Guertin KR, Hamilton MM, Haynes NE, Liu B, Qi L, Ren Y, Scott NR, So SS, Spence C, Taub R, Thakkar K, Tilley JW, Zwingelstein C.

Bioorg Med Chem Lett. 2014 Jun 15;24(12):2707-11. doi: 10.1016/j.bmcl.2014.04.049. Epub 2014 Apr 21.

PMID:
24815509
6.

Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.

Gillespie P, Goodnow RA Jr, Saha G, Bose G, Moulik K, Zwingelstein C, Myers M, Conde-Knape K, Pietranico-Cole S, So SS.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):949-53. doi: 10.1016/j.bmcl.2013.12.063. Epub 2013 Dec 24.

PMID:
24412066
7.

7-Phenyl-pyrido[2,3-d]pyrimidine-2,4-diamines: novel and highly selective protein tyrosine phosphatase 1B inhibitors.

Cheung AW, Banner B, Bose J, Kim K, Li S, Marcopulos N, Orzechowski L, Sergi JA, Thakkar KC, Wang BB, Yun W, Zwingelstein C, Berthel S, Olivier AR.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7518-22. doi: 10.1016/j.bmcl.2012.10.035. Epub 2012 Oct 16.

PMID:
23122867
8.

The emerging role of the intestine in metabolic diseases.

Bradley WD, Zwingelstein C, Rondinone CM.

Arch Physiol Biochem. 2011 Jul;117(3):165-76. doi: 10.3109/13813455.2011.578651. Review.

PMID:
21671708
9.

The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease.

Schmitt EK, Riwanto M, Sambandamurthy V, Roggo S, Miault C, Zwingelstein C, Krastel P, Noble C, Beer D, Rao SP, Au M, Niyomrattanakit P, Lim V, Zheng J, Jeffery D, Pethe K, Camacho LR.

Angew Chem Int Ed Engl. 2011 Jun 20;50(26):5889-91. doi: 10.1002/anie.201101740. Epub 2011 May 11. No abstract available.

PMID:
21563281
10.

Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial.

Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, Opal S; CAPTIVATE Trial Group.

Am J Respir Crit Care Med. 2011 Jun 1;183(11):1561-8. doi: 10.1164/rccm.201007-1167OC. Epub 2011 Feb 4.

PMID:
21297074
11.

Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors.

Jahnke W, Blommers MJ, Fernández C, Zwingelstein C, Amstutz R.

Chembiochem. 2005 Sep;6(9):1607-10. No abstract available.

PMID:
16028302
12.

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettilä V, Sprung CL, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA; OPTIMIST Trial Study Group.

JAMA. 2003 Jul 9;290(2):238-47.

PMID:
12851279
13.

Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, Zwingelstein C, Percell S, Shu V, Leighton A, Creasey AA.

Crit Care Med. 2001 Nov;29(11):2081-9.

PMID:
11700399
14.

Residues in transmembrane regions III and VI contribute to the 5-ht6 receptor ligand binding site.

Boess FG, Monsma FJ Jr, Bourson A, Zwingelstein C, Sleight AJ.

Ann N Y Acad Sci. 1998 Dec 15;861:242-3. No abstract available.

PMID:
9928266
15.

Correlation between 5-HT7 receptor affinity and protection against sound-induced seizures in DBA/2J mice.

Bourson A, Kapps V, Zwingelstein C, Rudler A, Boess FG, Sleight AJ.

Naunyn Schmiedebergs Arch Pharmacol. 1997 Dec;356(6):820-6.

PMID:
9453469
16.

Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor.

Boess FG, Monsma FJ Jr, Meyer V, Zwingelstein C, Sleight AJ.

Mol Pharmacol. 1997 Sep;52(3):515-23.

PMID:
9284367
17.

p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.

Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A.

JAMA. 1997 May 21;277(19):1531-8.

PMID:
9153367
18.

Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells.

Boess FG, Monsma FJ Jr, Carolo C, Meyer V, Rudler A, Zwingelstein C, Sleight AJ.

Neuropharmacology. 1997 Apr-May;36(4-5):713-20.

PMID:
9225298
19.

Pharmacologic evaluation of the discriminative stimulus of metachlorophenylpiperazine.

Bourson A, Wanner D, Wyler R, Petit N, Zwingelstein C, Rudler A, Sleight AJ.

Pharmacol Biochem Behav. 1996 Jan;53(1):107-14.

PMID:
8848438
20.

Identification of 5-hydroxytryptamine7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment.

Sleight AJ, Carolo C, Petit N, Zwingelstein C, Bourson A.

Mol Pharmacol. 1995 Jan;47(1):99-103.

PMID:
7838138
21.

Ceftriaxone--bilirubin-albumin interactions in the neonate: an in vivo study.

Martin E, Fanconi S, Kälin P, Zwingelstein C, Crevoisier C, Ruch W, Brodersen R.

Eur J Pediatr. 1993 Jun;152(6):530-4.

PMID:
8335024
22.

[CHANGES IN THE ION COMPOSITION OF VARIOUS TISSUES AS A FUNCTION OF SEX IN THE RAT SUBJECTED TO A STRESS].

ZWINGELSTEIN C, JOUANNETEAU J, PERES G.

J Physiol (Paris). 1964 May-Jun;56:467. French. No abstract available.

PMID:
14219881

Supplemental Content

Loading ...
Support Center